ASX-LISTED pharmaceutical research company Pharmaxis has announced its drug Bronchitol (mannitol) has now been funded in an indication extension on the Pharmaceutical Benefits Scheme (PBS), expanding cystic fibrosis (CF) patients' access to a portable treatment to help clear their lungs.
Effective from 01 Jan, eligible people with cystic fibrosis who are taking Pulmozyme (dornase alfa), another CF medication, will be able to add reimbursed Bronchitol to their treatment regime.
CF is a genetic condition affecting one in every 2,500 babies, with Bronchitol indicated for appropriate CF patients over six years of age.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jan 18
